[{"id":"172cf19e-4d47-4409-b143-492fc8df438e","acronym":"GPC3","url":"https://clinicaltrials.gov/study/NCT06726161","created_at":"2025-02-26T10:02:26.236Z","updated_at":"2025-02-26T10:02:26.236Z","phase":"Phase 1","brief_title":"Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC","source_id_and_acronym":"NCT06726161 - GPC3","lead_sponsor":"RayzeBio, Inc.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 01/01/2031","study_completion_date":" 01/01/2031","last_update_posted":"2024-12-10"},{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"},{"id":"2ffdf6d6-d9b4-4d82-87df-b8731e5b67ba","acronym":"ARYA3","url":"https://clinicaltrials.gov/study/NCT04864054","created_at":"2021-04-28T12:52:53.604Z","updated_at":"2024-07-02T16:35:05.862Z","phase":"Phase 2","brief_title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","source_id_and_acronym":"NCT04864054 - ARYA3","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stivarga (regorafenib) • ECT204"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-06"},{"id":"a2db800b-7773-424d-82b2-c62ae0087071","acronym":"","url":"https://clinicaltrials.gov/study/NCT05022927","created_at":"2021-08-26T12:53:07.004Z","updated_at":"2024-07-02T16:35:19.713Z","phase":"Phase 1","brief_title":"A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05022927","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974"],"overall_status":"Recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-12"},{"id":"f006991a-381f-4af1-aee4-1aabbfd0f738","acronym":"","url":"https://clinicaltrials.gov/study/NCT06088459","created_at":"2023-10-18T16:14:28.892Z","updated_at":"2024-07-02T16:35:32.927Z","phase":"Phase 1","brief_title":"NWRD06 DNA Plasmid for HCC After Radical Resection","source_id_and_acronym":"NCT06088459","lead_sponsor":"Newish Technology (Beijing) Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-18"},{"id":"fffdbde6-56a8-452b-bbea-6d93185cfd92","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928677","created_at":"2021-06-16T18:52:52.175Z","updated_at":"2024-07-02T16:35:44.506Z","phase":"Phase 1","brief_title":"A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment","source_id_and_acronym":"NCT04928677","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e codrituzumab (RG7686)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-06-28"},{"id":"28d0bd62-5b35-49f3-a30f-5616172cf246","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263960","created_at":"2022-03-03T14:06:10.705Z","updated_at":"2024-07-02T16:36:09.149Z","phase":"Phase 1/2","brief_title":"A Study of CM350 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05263960","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CM350 • Kangyueda (stapokibart)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 04/21/2022","start_date":" 04/21/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2022-06-09"},{"id":"95ff12bc-e7be-49e9-8642-0f09820d5e2a","acronym":"BK2016.01","url":"https://clinicaltrials.gov/study/NCT03146637","created_at":"2021-01-19T14:08:20.070Z","updated_at":"2024-07-02T16:36:35.301Z","phase":"Phase 2","brief_title":"Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer","source_id_and_acronym":"NCT03146637 - BK2016.01","lead_sponsor":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e activated CIK and bispecific antibody • activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/01/2017","start_date":" 05/01/2017","primary_txt":" Primary completion: 01/27/2021","primary_completion_date":" 01/27/2021","study_txt":" Completion: 01/28/2021","study_completion_date":" 01/28/2021","last_update_posted":"2021-02-01"},{"id":"19a59b05-6fa7-49a1-a054-e38013d0c27a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01507168","created_at":"2021-01-18T06:20:00.730Z","updated_at":"2024-07-02T16:36:46.674Z","phase":"Phase 2","brief_title":"A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma","source_id_and_acronym":"NCT01507168","lead_sponsor":"Hoffmann-La Roche","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e codrituzumab (RG7686)"],"overall_status":"Completed","enrollment":" Enrollment 185","initiation":"Initiation: 02/02/2012","start_date":" 02/02/2012","primary_txt":" Primary completion: 08/20/2015","primary_completion_date":" 08/20/2015","study_txt":" Completion: 08/20/2015","study_completion_date":" 08/20/2015","last_update_posted":"2020-04-03"},{"id":"5506a039-637a-4f14-9feb-30df14fa6ca9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02748837","created_at":"2021-03-26T08:15:12.358Z","updated_at":"2024-07-02T16:36:56.662Z","phase":"Phase 1","brief_title":"A Study of ERY974 in Patient With Advanced Solid Tumors","source_id_and_acronym":"NCT02748837","lead_sponsor":"Chugai Pharmaceutical","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERY974"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2019","primary_completion_date":" 08/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2019-08-22"}]